Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAT2A | P31153 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31229473 | 0.85 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTMEN1POLBKMT2A | |
| SCHEMBL30920847 | 0.82 | KDM4E (0.39) | SMN1; SMN2MAPTTOP2AMEN1POLB | |
| SCHEMBL29909120 | 0.79 | TOP2A (0.54) | SMN1; SMN2MAPTTOP2AMEN1POLB | |
| SCHEMBL30978986 | 0.79 | TOP2A (0.39) | SMN1; SMN2MAPTTOP2AMEN1KMT2A | |
| SCHEMBL30979136 | 0.78 | KDM4E (0.36) | SMN1; SMN2MAPTTOP2AKDM4ETP53 | |
| SCHEMBL30961058 | 0.78 | KDM4E (0.36) | SMN1; SMN2MAT2AMAPTTOP2AMEN1 | |
| SCHEMBL30048544 | 0.78 | MAPT (0.39) | SMN1; SMN2MAPTKDM4E | |
| SCHEMBL23601428 | 0.74 | MAT2A (0.48) | SMN1; SMN2MAT2AMAPT | |
| SCHEMBL30978994 | 0.74 | TOP2A (0.40) | SMN1; SMN2MAT2AMAPTTOP2AKDM4E | |
| SCHEMBL30979084 | 0.74 | TOP2A (0.43) | MAT2AMAPTTOP2AKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | SMN1; SMN2 4737/4885MAT2A 1551/4885MAPT 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.